Blood Brain Barrier (BBB) Disruption for Alzheimer's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer's DiseaseBlood Brain Barrier (BBB) Disruption - Device
Eligibility
50 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new tool to see if it can help patients with Alzheimer's by disrupting the blood-brain barrier.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 5 years

5 years
Device and procedure related adverse events
Hour 24
BBB Disruption and Closure

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Blood Brain Barrier (BBB) Disruption
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Blood Brain Barrier (BBB) Disruption · No Placebo Group · N/A

Blood Brain Barrier (BBB) Disruption
Device
Experimental Group · 1 Intervention: Blood Brain Barrier (BBB) Disruption · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

InSightecLead Sponsor
86 Previous Clinical Trials
3,512 Total Patients Enrolled

Eligibility Criteria

Age 50 - 85 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to communicate sensations during the ExAblate MRgFUS procedure.
You are taking the medication for Alzheimer's disease.
You are between 50 and 85 years of age.
You have probable AD.\n